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ABOUT THE JOURNAL 
 
 
Aims and Scope 
Molecular Therapy — Methods & Clinical Development is an 
international, open-access journal publishing top-quality, 
novel methods and technology development, as well as 
significant improvements to established research 
techniques in basic, translational, and clinical cell and gene 
therapy. As an official journal of the American Society of 
Gene & Cell Therapy, Molecular Therapy — Methods & 
Clinical Development builds upon the success of Molecular 
Therapy in publishing important peer-reviewed methods 
and procedures, as well as cutting-edge reviews and 
commentaries targeted to technological and 
methodological advances in the broad array of fields under 
the molecular therapy umbrella. 
 
Key topics include: 
 
• Gene vector engineering and production 
• Methods for targeted genome editing and 
engineering 
• Methods and technology development for cell 
reprogramming and directed differentiation of 
pluripotent cells 
• Methods for gene and cell vector delivery 
• Development of biomaterials and nanoparticles 
for applications in gene and cell therapy and 
regenerative medicine 
• Analysis of gene and cell vector biodistribution 
and tracking 
• Pharmacology/toxicology studies of new and 
next-generation vectors 
• Methods for cell isolation, engineering, culture, 
expansion, and transplantation 
• Cell processing, storage, and banking for 
therapeutic application 
• Preclinical and QC/QA assay development 
• Translational and clinical scale-up and Good 
Manufacturing procedures and process 
development 
• Clinical protocol development 
• Computational and bioinformatic methods for 
analysis, modeling, or visualization of biological 
data 
• Negotiating the regulatory approval process and 
obtaining such approval for clinical trials 
 
Molecular Therapy — Methods & Clinical Development is a 
peer-reviewed, open-access, online-only journal that 
publishes Original Articles, Reviews, Commentaries, 
Letters to the Editor, and Editorials. 
 
 
Journal Details 
 
Editor-in-Chief:   
Roland W. Herzog, Ph.D. 
Department of Pediatrics 
University of Florida College of Medicine 
 
Editor: 
Robert M. Frederickson, PhD 
 
Send an e-mail to the editor 
 
Manuscript submission website: 
http://mts-mtm.nature.com/cgi-bin/main.plex 
 
 
Abstracted/indexed in: 
PubMed Central/PubMed 
Google Scholar 
DOAJ 
Chemical Abstracts 
Copyright Clearance Center 
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ARTICLE TYPE SPECIFICATIONS 
 
 
Article Description Abstract Unsolicited considered? 
Word Limit/ 
Tables/Figures 
Original Articles 
 
These are investigational studies presenting 
basic and/or preclinical studies applying gene 
therapy or other molecular medicine 
interventions to specific disease models or 
biological problems; studies aimed at 
establishing proof-of-principle for novel 
therapeutic approaches; studies defining new 
methodological tools or improving established 
methods; and reports on the results of human 
clinical trials of gene therapy and other 
molecular medicine approaches to disease. 
Studies should be organized as follows: Title 
page, Abstract, Introduction, Results, 
Discussion, Materials & Methods, Conflict of 
Interest, Acknowledgment, Supplementary 
Material, References, Tables, Figure Legends. 
Manuscripts that do not conform to these 
guidelines will be returned to the author for 
correction prior to review. 
 
Unstructured 
abstract of no 
more than 200 
words 
 
 
Yes  
No word limit, but 
a limit of 8 display 
items (figures plus 
tables). Additional 
items can be 
published online 
only as 
supplementary 
material. Lengthy 
papers may be 
returned to authors 
for additional 
editing. 
  
Review Articles 
Written by recognized experts and not only 
outline the "state of the art," but also try to 
project future directions.  
 
Unstructured 
abstract of no 
more than 200 
words  
 
 
Reviews are 
commissioned, 
but suggestions 
for articles will be 
evaluated for 
interest to the 
readership 
3,000-4,000 words 
Comment 
These are short descriptions and analyses of 
important research published in Molecular 
Therapy — Methods & Clinical Development or 
elsewhere, events in gene therapy, or social, 
ethical, or political issues of interest to Molecular 
Therapy — Methods & Clinical Development 
readers. Comments are the opinion of the 
author, not the editorial board or the ASGCT.  
 
No abstract  
 
 
Comments are 
commissioned, 
but the editorial 
teams welcome 
unsolicited 
contributions for 
consideration 
~1,200 words 
Correspondence 
Correspondence are short, succinct statements 
and/or opinions responding to articles 
published in Molecular Therapy — Methods & 
Clinical Development or commenting on 
methodological advances that have an impact 
on the gene and cell therapy communities as a 
whole. All Correspondence are subject to 
editing and possible abridgment. 
No abstract 
 
 
Yes  n/a 
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Protocols 
 
Protocols are a “recipe-style” step-by-step 
description of a procedure of potentially broad 
interest to the journal; for example, production 
of minicircle DNA; ex vivo gene transfer to 
murine hematopoietic stem cells using lentiviral 
vectors; hydrodynamic delivery of DNA to 
mouse liver. Molecular Therapy – Methods & 
Clinical Development requires “Protocol” articles 
formatted from the Abstract to the Anticipated 
Results in the style of Nature Protocols. Please 
adhere to the formatting directions pertaining to 
these sections. 
 
Unstructured 
abstract of no 
more than 200 
words 
No 
No word or artwork 
limit. 
Max 50 references 
PREPARATION OF ARTICLES 
 
Molecular Therapy — Methods & Clinical Development requires 
electronic submission of manuscripts. Detailed instructions 
are at our manuscript submission website. For questions 
regarding your submission, contact the Editorial Office via 
e-mail. Complete submissions contain all items below, and 
submissions are dated according to receipt of all items. No 
editorial decision will be communicated to the authors until 
the submission is complete. All submissions must include: 
*Cover letter stating: 
1. The data in the manuscript is original and the 
manuscript is not under consideration elsewhere. 
2. None of the manuscript contents has been 
previously published except in abstract form. 
3. All authors have read and approved all versions of 
the manuscript, its content, and its submission to 
Molecular Therapy — Methods & Clinical 
Development. 
4. You agree to pay the article processing charge if 
your paper is accepted ($2500 for manuscripts with 
a first or corresponding/senior author who is an 
Active ASGCT Member OR $3200 for manuscripts 
with a first or corresponding/senior author who 
are non-ASGCT members or associate ASGCT 
members). 
5. The corresponding author's address, telephone, 
fax, and email (email address required). 
 
*Any Conflict of Interest statement should be included 
in the paper's Conflict of Interest section, not the cover 
letter. 
General Style 
As the electronic submission will provide the basic material 
for typesetting, it is important that papers are prepared in 
the general editorial style of the journal. 
1. See the artwork guidelines PDF for information on 
labeling of figures 
2. Do not make rules thinner than 1pt (0.36mm) 
3. Use a coarse hatching pattern rather than shading 
for tints in graphs 
4. Color should be distinct when being used as an 
identifying tool 
5. 5.Use Si units throughout 
6. 6.Spaces, not commas should be used to separate 
thousands 
7. Abbreviations should be preceded by the words for 
which they stand in the first instance of use 
8. Text should be double spacing with a wide margin 
9. Use a common word-processing package (such as 
Microsoft Word) for the text. Embed tables 
converted into images at the end of the Word 
document, or as a separate file in whichever 
program you used to generate them 
10. If you submit raw data, this can be done in Excel, 
or tab/comma delimited format 
11. At first mention of a manufacturer the town, (state 
if USA) and country should be provided 
12. Microsoft Office 2007 saves files in an XML format 
by default (file extensions .docx, .pptx and xlsx). 
Files saved in this format cannot be accepted for 
publication ; therefore, ensure files are saved using 
the file extension .doc  
Title page – Page 1 
The title page should include the following: 
• Brief, informative title of 120 characters or less 
• Authors' full names, departments, and institutions 
(indicate affiliations numerically with numbers placed 
after authors' names and before the institutions; indicate 
the corresponding author using the format 
"Correspondence should be addressed to J.A.S. 
(johnsmith@university.edu)" 
• City, state and country in which the work was done 
• Corresponding author's address, telephone, fax and 
email (email address required) 
• Short title of 50 characters or less, including spaces 
Abstract – Page 2 
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• Must be a single paragraph and not exceed 200 words 
• Briefly summarize the main findings of the paper 
without headings 
• Do not include abbreviations, acknowledgments, or refer 
to footnotes or references –Write with a general scientific 
audience in mind 
Introduction 
The article should begin with a brief introductory statement 
that places the work to follow in perspective and explains 
its intent and significance. The Introduction should be as 
concise as possible and should not be longer than two 
double-spaced typed pages. 
Results 
The Results section should briefly present the data in text, 
tables or figures. 
Discussion 
The Discussion should focus on the interpretation and 
significance of the findings with concise objective comments 
that describe their relation to other work in the area. It 
should not repeat information in Results. The final 
paragraph should highlight the main conclusion(s), and 
provide some indication of the direction future research 
should take. 
 Materials and Methods 
Readers should be able to reproduce the experiments from 
the information in the methods section, figure legends, table 
footnotes, and references. Provide the manufacturer's name 
and location (city, state if within the US; city, country if 
outside the US) for materials purchased.  
Manuscripts must include a statement that all human and 
animal studies have been approved by the authors' 
Institutional Review Board, and, for human studies, 
Molecular Therapy — Methods & Clinical Development requires 
a statement confirming the Declaration of Helsinki 
protocols were followed and that patients gave their 
written, informed consent, as well as the trial registration 
number of the study. Molecular Therapy — Methods & 
Clinical Development subscribes to the standards set by the 
International Committee of Medical Journal Editors (ICMJE) 
in 2004, requiring all trials that start enrolling participants 
after July 1, 2005 must be registered in a suitable publicly 
accessible register before that date in order to be considered 
for publication. For more information on Molecular Therapy 
— Methods & Clinical Development policy related to clinical 
trials, click here. 
Additionally, new nucleotide data must be submitted and 
deposited in the DDBJ/EMBL/GenBank databases and an 
accession number obtained before the paper can be 
accepted for publication. Restrictions on material 
availability must be disclosed in the manuscript's Materials 
and Methods section, and should include details of how 
materials and information may be obtained. For more 
information on database deposition, click here. 
Conflict of Interest 
The Conflict of Interest section is mandatory. All authors are 
expected to disclose all funding sources - institutional and 
corporate – as well as any commercial affiliations or 
consultancies, stock, or equity interests, or patent-licensing 
arrangements that could be considered to pose a financial 
conflict of interest related to the submitted manuscript. This 
information must be included at this stage and will be 
published as part of the paper. 
Acknowledgments 
These should be brief, and should include sources of 
support or funding including sponsorship (e.g. university, 
charity, commercial organization) and sources of material 
(e.g. novel drugs) not available commercially. These can also 
include personal thanks and author contributions. Work 
done by a contributor or medical writer that does not 
qualify him/her for authorship, but which warrants 
acknowledgment, should be noted here. 
In both sections, individuals should be referred to by their 
full first name and surname, with their affiliation in 
parentheses. Titles (Dr., Professor, Mrs., etc.) are not 
permitted. 
See Conflict of Interest in the Editorial Policy section for 
detailed information and requirements. 
References 
Only articles that have been published or are in press should 
be included in the reference list. Unpublished results or 
personal communications should be cited as such in the text, 
in parentheses. Personal communications must include the 
source's name and the year, e.g., "(L. Chen, personal 
communication, 2013)". Submitted manuscripts should be 
cited as follows: "(J. Smith and R. Davis, manuscript 
submitted)." 
References should be cited in the text in numerical order (1, 
2, 3, ..., n), in order of appearance. The citations should be 
superscripted (for example, "Jones and colleagues3 found 
that..."). Arrange the reference list in numerical order 
beginning with the references cited in the text, followed by 
those cited only in the figure legends and tables. For 
references with more than six authors, list the first six 
authors followed by et al. The titles of journals should be 
abbreviated according to PubMed. 
Samples: 
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1. Zhong, L, Archer, ESJ, Holmgren, A, Smith, J, 
Taylor, NM Jr, Franklin BR III et al. (2000). 
Structure of mammalian thioredoxin reductase. 
Proc Natl Acad Sci USA 92: 1311-1319. 
2. Hagag, N and Viola, MV (1993). Chromosome 
Microdissection and Cloning: A Practical Guide, 
Academic Press, San Diego, 179pp. 
3. Harley NH, Vivian L (1974). Invading 
microorganisms. In: Sodeman WA, Smith A (eds). 
Mechanisms of Disease, 4th edn. Saunders: 
Philadelphia, pp 457–472. 
4. US Department of Health and Human Services. 
Hypertension in the United States, 2009. Report 
12345, pp 445-449. Washington, DC: US 
Government Printing Office, 2010. 
5. World Health Organization (2011). Management of 
severe malnutrition: a manual for physicians 
<http://whqlibdoc.who.int/hq/1999/a57361.pdf. 
Tables 
Tabular presentations should be self-explanatory and not 
duplicate content in the text. Tables should be presented at 
the end of the manuscript (one table per page), numbered 
sequentially (1, 2, 3) and cited in chronological order in the 
text. Each table should include an informative title. Do not 
provide a table legend, but supply information such as the 
description of the experiment, definition of columns or 
abbreviations, etc. in footnotes to the title and table 
contents. Label footnotes with superscripted lowercase 
Arabic letters (a, b, c, etc.), not symbols. Define errors in the 
table by a footnote, e.g., "mean+SD" or "mean+SEM". 
Authors should ensure that the data in the tables are 
consistent with those cited in the relevant papers in the text, 
totals add up correctly, and percentages have been 
calculated correctly. Authors must submit tables in 
Microsoft Word format. 
Figures 
Illustrative material should complement the text. Figures 
should be labeled sequentially (1, 2, 3) and cited in the text, 
but not embedded within the text. Figures should be 
submitted as separate files. Figures should be high-
resolution (at least 300 dpi for photos and 1000 dpi for line 
art/graphs) TIFF or EPS files, and the files combined should 
not exceed 25 MB. PowerPoint figures are not suitable for 
publication. Figure panels are denoted with boldface, 
lowercase Arabic letters, non-serif font (a, b, c, etc.) and are 
cited in the text as follows: (Fig. 1a) (Figs. 1a,b) (Figs 1a-c) 
(Figs. 1 and 2b). (Figure subpanels, for example b1, b (i), Ba, 
etc., are not permitted.) In figure legends, panel 
designations are always enclosed in parentheses -- (a) (b, c) 
– unless referred to directly, when parentheses are omitted: 
"Scale bars as in a." Authors should avoid bar or line graphs 
with only two data points. Such results may be described in 
the text only. Overall to save space, the author should aim 
for efficient and compact presentation of data and should 
avoid an excessive number of panels per figure. 
Detailed guidelines for submitting artwork can be found by 
downloading the artwork guidelines PDF. Using the 
guidelines, please submit production quality artwork with 
your initial online submission. Please also see here for our 
policy on image manipulation. 
Color figures 
Color figures are published in Molecular Therapy — Methods 
& Clinical Development free of charge. 
Figure sizing 
To avoid size reduction, authors should submit artwork of 
exact column measurements and crop out unnecessary areas 
(1 column = 87.50mm; 2 columns = 180mm). Most figures 
should be presented at 1 column width (or quarter page in 
size). 
Figure legends 
Captions should be presented as part of the main text 
document of the manuscript. The figure title should be 
given in the legend, not on the figure. Legends should 
explain how an experiment was done and identify parts of 
the figure (i.e., a, b, c), not interpret the figure. Indicate the 
meaning of all symbols, keys and abbreviations used in the 
figure. Error bars should be defined in the legend as "mean 
+ SD" or "mean + SEM". If you use SEM, give “n” for each 
point. Figure legends should not state or interpret the 
results or editorialize upon them; such statements should be 
included in the main Results or Discussion text, 
respectively. 
Line drawings 
Drawings should have clear, uniform lines of thickness. 
Curves should be smooth. Do not use 3-dimensional graphs 
unless the third dimension is used for data. Label axes 
parallel to the axis, not at the top of the graph. Labels must 
be clearly legible. Use only black and white, not gray, in 
charts and graphs. The inside of bar graphs should use a 
patterned black and white print. 
Photomicrographs 
A scale bar, not magnification, must be placed on 
micrographs and the scale indicated in the legend, e.g., 
"scale bar = 1 mm". 
Permission 
If a table or figure has been published or copyrighted, the 
authors must obtain written permission from the copyright 
owner to reproduce the material in both print and electronic 
formats and submit the authorization with the manuscript. 
This applies to quotes, illustrations and other materials 
taken from previously published works not in the public 
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domain. The original source should be cited in the figure 
caption or table footnote. 
Supplementary material 
Supplementary material is peer-reviewed material directly 
relevant to the conclusion of an article that cannot be 
included in the printed version owing to space or format 
constraints. It is posted on the journal's web site and linked 
to the article when the article is published and may consist 
of data files or extensive tables. The article must be 
complete and self-explanatory without the supplementary 
material. Supplementary material enhances a reader's 
understanding of the paper but is not essential to that 
understanding. 
Supplementary material must be supplied to the editorial 
office in its final form for peer review. Supplementary 
material should be cited in the text as "Figure S1, S2, etc.," 
"Table S1, S2, etc." or "Supplementary Materials and 
Methods.” 
Supplying supplementary material files: Supplementary 
material must be supplied in its FINAL format via eJP and 
should contain titles, descriptions and legends. It is not 
subedited and files will appear online exactly as originally 
submitted. Supplementary material must be submitted as a 
single combined PDF (file size should not exceed 25 MB in 
total including supplemental files; for individual files, 1 MB 
each), except for files that cannot be in PDF form (such as 
movies and extensive tables), which can be submitted 
separately. Format as below, listing figures first, followed 
by tables, then materials and methods: 
Supplementary Material 
Figure S1. Schematic diagram of automatic EEG analysis. 
Table S1. Sequences of hairpin siRNA inserts used in this 
study. 
For files that cannot be submitted in PDF form, please 
identify the types of files (file formats) submitted and 
include a text summary (no more than 50 words) to describe 
the contents of each file within the text of the manuscript, 
placed after the Acknowledgments. 
For separate dataset and spreadsheet files that cannot be 
included in the PDF, we can accept any of these formats. 
Please note: We do not accept TeX and LaTeX.  
Graphical image files (.gif) HTML files (.html) MPEG movie 
files (.mpg) JPEG image files (.jpg), plain ASCII text (.txt) 
Acrobat files (.pdf) MS Word documents (.doc) Postscript 
files (.ps) MS Excel spreadsheet documents (.xls) 
Powerpoint files (.ppt).  
File sizes must be as small as possible, so that they can be 
downloaded quickly. Images should not exceed 640 x 480 
pixels (9 x 6.8 inches at 72 pixels per inch). If applicable to 
the presentation of the supplementary material, use a 256 
color palette. Please consider the use of lower specification 
for all of these points if the supplementary material can still 
be represented clearly. At the Editor's discretion, large 
tables, data sets, etc. of accepted manuscripts may be 
published as supplementary material on the Molecular 
Therapy – Methods & Clinical Development website only. 
English Language Support 
For editors and reviewers to accurately assess the work 
presented in your manuscript you need to ensure the 
English language is of sufficient quality to be understood. If 
you need help with writing in English you should consider: 
 
• Asking a colleague who is a native English speaker to 
review your manuscript for clarity.  
• Visiting the English language tutorial which covers the 
common mistakes when writing in English. 
• Using a professional language editing service where 
editors will improve the English to ensure that your 
meaning is clear  
 
and identify problems that require your review. Two 
such services are provided by our affiliates Nature 
Research Editing Service and American Journal 
Experts. 
 
Please note that the use of a language editing service is not a 
requirement for publication in this journal and does not 
imply or guarantee that the article will be selected for peer 
review or accepted. 
 
If your manuscript is accepted it will be checked by our 
copyeditors for spelling and formal style before publication.
 
 
HOW TO SUBMIT 
 
 
Pre-submission enquiries  
Please submit via our online manuscript submission system 
or via e-mail to methods@molther.org.  
 
Online submission 
We only accept manuscript submission via our online 
manuscript submission system. For technical questions with 
the submission site, please contact the Helpdesk. Before 
submitting a manuscript, authors are encouraged to consult 
our Editorial Policies section of the Instructions for Authors. 
If you have not already done so, please register for an 
account with our online manuscript system. You will be able 
to monitor the status of your manuscript online throughout 
the editorial process.  
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If you need additional help, you can click on help signs 
available throughout the system and a box will appear with 
context sensitive help. If further assistance is required, then 
please contact the MTS helpdesk. 
 
Submission of revisions 
Authors submitting a revised manuscript after review are 
asked to include the following: 
 
• A rebuttal letter, indicating point-by-point how 
you have addressed the comments raised by the 
reviewers. If you disagree with any of the points 
raised, please provide adequate justification in 
your letter. Please do not submit a cover letter with 
your resubmission and rebuttal letter.  
• A marked-up version of the manuscript that 
highlights changes made in response to the 
reviewers' comments in order to aid the Editors 
and reviewers.  
• A 'clean' (non-highlighted) version of the 
manuscript.
 
 
OPEN ACCESS AND POST-ACCEPTANCE 
 
 
Authors are not required to grant the copyright in their 
articles to the American Society of Cell and Gene Therapy, 
NPG, or Molecular Therapy — Methods & Clinical 
Development. Instead, authors grant Molecular Therapy — 
Methods & Clinical Development with an exclusive license. 
Authors are free to reuse their own papers in any future 
published work and on their own website or institutional 
repository. 
The corresponding author must instead complete and sign 
the License to Publish form upon acceptance of the 
manuscript and return it to the editorial office. Failure to 
do so will result in delays to the publication of your paper. 
A copy of the License to Publish form will be sent to you at 
the Accept stage. The following methods of signing the 
license are acceptable according to the author’s preference: 
a handwritten digital signature, insertion of a digital image 
of a physical signature, or a typed name with or without 
encryption. NPG's author license page provides details of 
the policy and a sample form. 
Government employees from the United States or Canada 
are required to sign instead a government employee form. 
For a copy of this form, should your article be accepted, 
please contact the journal production editor 
M.Karmelek@us.nature.com . 
 
Open access publication 
Open Access articles can be published under one of three 
Creative Commons licenses, at the free choice of the 
authors. 
Under the Creative Commons Attribution-
Noncommercial-Share Alike 4.0 International License 
(CC BY-NC-SA), users are free to share (copy, distribute 
and transmit) and remix (adapt) the contribution under the 
following conditions (read full legal code): 
• Attribution. Users must attribute the contribution 
in the manner specified by the author or licensor 
(but not in any way that suggests that they or 
their use of the contribution is endorsed by the 
author or licensor). 
• Noncommercial. Users may not use this work for 
commercial purposes. 
• Share Alike. If users alter, transform, or build 
upon this work, they may distribute the resulting 
work only under the same or similar license to 
this one. 
Under the Creative Commons Attribution-
Noncommercial-No Derivative Works 4.0 International 
License (CC BY-NC-ND), users are free to share (copy, 
distribute and transmit) the contribution under the 
following conditions (read full legal code): 
• Attribution. Users must attribute the contribution 
in the manner specified by the author or licensor 
(but not in any way that suggests that they or 
their use of the contribution is endorsed by the 
author or licensor). 
• Non-commercial. Users may not use this 
contribution for commercial purposes. 
• No derivative works. Users may not alter, 
transform, or build upon this work. 
Under the Creative Commons Attribution 4.0 
International License, users are free to share (copy, 
distribute and transmit) and remix (adapt) the 
contribution, even commercially, under the following 
conditions (read full legal code): 
• Attribution. Users must attribute the contribution 
in the manner specified by the author or licensor 
(but not in any way that suggests that they or 
their use of the contribution is endorsed by the 
author or licensor)  
Authors should note that some funders require papers to 
be published under a specific license and so should check 
the funder mandate to ensure compliance. 
Waiver of institutional open access policies 
 
Please note that Harvard University FAS, MIT, Princeton, 
UCSF, University of Hawaii at Manoa, California Institute 
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of Technology (Caltech) and the Georgia Institute of 
Technology have enacted Open Access policies that 
conflict with our own policy for articles published via the 
subscription route. If any corresponding or contributing 
authors are from these institutions, you will need to 
provide a waiver from the institution of every affected 
author, which can be obtained from the institution. This 
waiver should be submitted at the same time as the 
Licence to Publish form. This requirement does not apply 
to articles published via the open access route. 
 
Proofs  
The corresponding author will receive an e-mail containing 
a URL linking to the proofing site. Proof corrections must 
be returned within 48 hours of receipt. Failure to do so may 
result in delayed publication. Extensive corrections cannot 
be made at this stage.
 
 
COSTS 
 
 
Article Processing Charges 
For manuscripts with a first or corresponding/senior 
author who is an active ASGCT member, the article 
processing charge for Open Access papers is 
£1,700/$2,500/€2,137 (plus VAT where applicable) for 
papers published under the Creative Commons 
Attribution-Noncommercial-Share Alike 4.0 
International License and Creative Commons 
Attribution-Noncommercial-No Derivative Works 4.0 
International License, or £1,800/$2,600/€2,200 for articles 
published under the Creative Commons Attribution 4.0 
International License. 
For manuscripts without a first or corresponding/senior 
author who is an active ASGCT member, the article 
processing charge for Open Access papers is 
£2,500/$3,200/€2,900 (plus VAT where applicable) for 
papers published under the Creative Commons 
Attribution-Noncommercial-Share Alike 4.0 
International License and Creative Commons 
Attribution-Noncommercial-No Derivative Works 4.0 
International License, or £2,600/$3,400/€3,000 for articles 
published under the Creative Commons Attribution 4.0 
International License. 
Papers published under the Creative Commons 
Attribution 4.0 International License are charged a 
premium APC as this license grants greater end user rights 
including commercial reuse of the work. For more 
information on this license please see the press release. 
Upon acceptance, it is mandatory that authors fill out and 
send back the payment form along with their license to 
publish form. 
With regards to payment, usual credit terms are 30 days 
from receipt of invoice. Failure to pay your invoice within 
the stated credit term may result in such penalties as 
restrictions on your ability to publish with Nature 
Publishing Group (NPG) or Molecular Therapy — Methods & 
Clinical Development in the future, involvement of a third 
party debt collection agency and legal proceedings. 
Open access funding 
Visit Nature Publishing Group's open access funding page 
for information about research funders and institutions 
that provide funding for open access. 
NPG also offers an APC support service to make it easier 
for NPG authors to discover and apply for open access 
funding. For advice on what funding is available to you 
and help in approaching funders and institutions, please 
contact us at apcwaivers@springernature.com. 
For more information about NPG's open access publishing 
options and policies, please see our open access homepage. 
Color and page charges 
There are no color or page charges for Molecular Therapy — 
Methods & Clinical Development. 
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EDITORIAL POLICIES 
 
Review policies 
Molecular Therapy — Methods & Clinical Development is 
committed to maintaining high standards for the integrity 
of the published scientific record. Authors should take note 
and adhere to the journal editorial policies noted below. The 
journal will investigate any instances of suspected scientific 
fraud, image manipulation, plagiarism, duplicate 
publication, undocumented sources of funding or conflicts 
of interest, and other cases that compromise research ethics 
or the journal's scientific integrity. Depending on the 
investigation, the journal may opt to publish corrections, or 
in serious cases of scientific misconduct, request that the 
authors retract their paper or impose a retraction on the 
paper.  
Review process 
To read about the process of review in Molecular Therapy — 
Methods & Clinical Development, Molecular Therapy — Nucleic 
Acids, and Molecular Therapy, read this editorial penned by  
the Editor, here (Frederickson, RF (2013). Getting Published 
in Molecular Therapy and Its Sibling Journals. Molecular 
Therapy 21: 1287–1288). 
All contributions that are selected for peer review are sent 
to two or more independent reviewers. The identity of 
reviewers is confidential and manuscripts are considered 
private information. Papers may be rejected without 
external review at the discretion of the editorial board 
following internal review. Authors are encouraged to 
suggest or recommend for exclusion reviewers at the time 
of submissions, as this can help speed the review process. 
 
Anonymity 
Reviewers' identities are not released to authors, except 
when reviewers specifically ask to be identified. If 
reviewers wish to reveal their identities while the 
manuscript is under consideration, this should be done 
through the Editor. Should a reviewer contact an author 
directly, we ask authors to inform the Editor as soon as 
possible. We prohibit any attempt by authors to confront 
reviewers or determine their identities. Our own policy is to 
neither confirm nor deny any speculation about reviewers' 
identities, and we encourage reviewers to adopt a similar 
policy. 
 
Clinical trials 
As defined by the International Committee of Medical 
Journal Editors (ICMJE), a clinical trial is any research 
project that prospectively assigns human subjects to 
intervention and comparison groups to study the cause-and-
effect relationship between a medical intervention and  
 
a health outcome. A medical intervention is any 
intervention used to modify a health outcome and includes 
but is not limited to drugs, surgical procedures, devices, 
behavioral treatments, and process-of-care changes. A trial 
must have at least one prospectively assigned concurrent 
control or comparison group in order to trigger the 
requirement for registration. Nonrandomized trials are not 
exempt from the registration requirement if they meet the 
above criteria. 
When reporting experiments on human subjects, it must be 
indicated whether the procedures were in accordance with 
the ethical standards of the responsible committee on 
human experimentation (institutional or regional) or with 
the Helsinki Declaration of 1975 (as revised in 1983). Include 
Institutional Review Board or Animal Care and Use 
Committee approvals. 
Molecular Therapy — Methods & Clinical Development 
subscribes to the standards set by the International 
Committee of Medical Journal Editors in The Lancet (364, 
911-912, 2004), requiring that all trials that start enrolling 
participants after July 1, 2005 must be registered in a 
suitable publicly accessible register before that date in order 
to be considered for publication in the Journal. Those trials 
that started enrollment before July 1, 2005 must register 
before September 13, 2005 to be considered for publication. 
Suggested registers include: Clinical Trials.Gov and Current 
Controlled Trials. Registration in the former is free, while 
registration for trials that do not emanate from developing 
countries carries a $144 charge in the latter. Access to both 
registries is free.  
NPG endorses the toolkits and guidelines produced by the 
following bodies: 
• Committee on Publication Ethics: 
http://publicationethics.org/ 
• Good Publication Practice: http://www.gpp-
guidelines.org/ 
• Medical Publishing Insights and Practices 
Initiative: http://www.mpip-initiative.org/ 
Conflict of Interest 
 
The Conflict of Interest section is mandatory. All authors 
must disclose all funding sources - institutional and 
corporate – as well as any commercial affiliations or 
consultancies, stock, or equity interests, or patent-licensing 
arrangements that could be considered to pose a financial 
conflict of interest related to the submitted manuscript. This 
information will be published as part of the paper.  
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When submitting a manuscript, the author is responsible 
for disclosing their own relevant interests in the work. If no 
potential conflict of interest exists, please note that the 
authors have nothing to disclose. 
The statement must contain an explicit and unambiguous 
statement describing any potential conflict of interest, or 
lack thereof, for any of the authors. Examples include "Jane 
Smith (Emory University) receives compensation as a 
consultant for XYZ Company," "Bill Jones and Jane Smith 
have financial holdings in ABC Company," or "Bill Jones 
owns a patent on the diagnostic device described in this 
report." These statements regarding conflicts of interest 
must be included in the manuscript under the heading 
“Conflict of Interest.”  
For the purposes of this statement, competing interests are 
defined as those of a financial nature that, through their 
potential influence on behavior or content, or from 
perception of such potential influences, could undermine 
the objectivity, integrity or perceived value of a publication. 
They can include any of the following:  
• Funding: Research support (including salaries, 
equipment, supplies, reimbursement for attending 
symposia, and other expenses) by organizations 
that may gain or lose financially through this 
publication. The role of the funding body in the 
design of the study, collection, and analysis of data 
and decision to publish should be stated. 
• Employment: Recent (while engaged in the 
research project), present or anticipated 
employment by any organization that may gain or 
lose financially through this publication. 
• Personal financial interests: Stocks or shares in 
companies that may gain or lose financially 
through publication; consultation fees or other 
forms of remuneration from organizations that 
may gain or lose financially; patents or patent 
applications whose value may be affected by 
publication. 
Neither the precise amount received from each entity nor 
the aggregate income from these sources needs to be 
provided. 
Examples of declarations are: 
• Conflict of Interest 
The authors declare no conflict of interest. 
• Conflict of Interest 
Lee Caron has received compensation as a member 
of the scientific advisory board of Acadia 
Pharmaceutical and owns stock in the company. 
He also has consulted for Lundbeck and received 
compensation. John Rothman (NYU Medical 
Center) and Sara Jensen (Columbia University) 
declare no potential conflict of interest. 
If subsequent to publication it is learned that relevant 
information was not disclosed, a corrigendum describing 
the infraction will be published in the journal and linked to 
the article in PubMed. Additional actions may be taken, 
including restrictions from publishing in the journal in the 
future and issuing a notice of concern to the author’s 
institution, depending on the outcome of journal 
investigation. 
When there is uncertainty about what should be listed, it is 
best to disclose all holdings or affiliations to ensure that 
there is no question about intent to withhold information. 
Authors should communicate with the editorial office 
(methods@molther.org) if they have questions about this 
policy. 
Acknowledgments 
These should be brief, and should include sources of 
support or funding including sponsorship (e.g. university, 
charity, governmental organization) and sources of material 
(e.g. novel drugs) not available commercially. These can also 
include personal thanks and author contributions. Work 
done by a contributor or medical writer that does not 
qualify him/her for authorship, but which warrants 
acknowledgment, should be noted here. 
Authorship 
 
Requirements for all categories of articles largely conform to 
the "Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals," developed by the ICMJE. A 
manuscript will be considered for publication with the 
understanding that: 
1. all named authors have agreed to its submission 
2. it is not currently being considered for publication 
by another journal 
3. if the paper is accepted, it will not subsequently be 
published in the same or similar form in any 
language without the consent of publisher 
Each author must have contributed sufficiently to the 
intellectual content of the submission. The corresponding 
author should list all authors and their contributions to the 
work. Any changes to the author list after submission, such 
as a change in the order of the authors, or the deletion or 
addition of authors, must be approved by a signed letter 
from every author. The corresponding author must confirm 
that he or she has had full access to the data in the study and 
final responsibility for the decision to submit for 
publication. To qualify as a contributing author, one must 
meet all of the following criteria: 
1. Conceived and/or designed the work that led to 
the submission, acquired data, and/or played an 
important role in interpreting the results 
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2. Drafted or revised the manuscript 
3. Approved the final version 
Individuals who made direct contributions to the work but 
do not meet all of the above criteria should be noted in the 
Acknowledgments section of the manuscript. 
Medical writers and industry employees can be authors or 
contributors. Their roles, affiliations, and potential conflicts 
of interest should be included in the author list or noted in 
either the Conflict of Interest or Acknowledgments section, 
concurrent with their contribution to the work submitted. 
Failure to acknowledge these contributors is considered 
inappropriate, which conflicts with Molecular Therapy — 
Methods & Clinical Development's editorial policy. 
Plagiarism and fabrication 
 
Plagiarism is when an author attempts to pass off someone 
else's work as his or her own. Duplicate publication, 
sometimes called self-plagiarism, occurs when an author 
reuses substantial parts of his or her own published work 
without providing the appropriate references. Plagiarism 
without dishonest intent is relatively frequent, for example, 
when an author reuses parts of an introduction from an 
earlier paper. 
CrossCheck is a multi-publisher initiative to screen 
published and submitted content for originality.  Molecular 
Therapy — Methods & Clinical Development uses CrossCheck 
to detect instances of overlapping and similar text in 
submitted manuscripts. To find out more about CrossCheck 
visit www.crossref.org/crosscheck.html. 
If plagiarism is suspected, as a member journal of the 
Committee on Publication Ethics (COPE), Molecular Therapy 
— Methods & Clinical Development will follow best industry 
practice to investigate the integrity of the research in 
question. Based on the outcome of this investigation, the 
journal may opt to publish a correction, or in serious cases 
of scientific misconduct, impose a retraction on the paper.   
Duplicate publication 
 
Papers must be original and not previously published or 
submitted for publication elsewhere. This rule also applies 
to non-English language publications. NPG allows and 
encourages prior publication on recognized community 
preprint servers for review by other scientists before formal 
submission to a journal. The details of the preprint server 
concerned and any accession numbers should be included 
in the cover letter accompanying manuscript submission. 
This policy does not extend to preprints available to the 
media or that are otherwise publicized outside the scientific 
community before or during the submission and 
consideration process. 
Image manipulation 
 
Images submitted with a manuscript for review should be 
minimally processed. Authors should retain their 
unprocessed data and metafiles, as Editors may require 
them to aid in manuscript evaluation. If unprocessed data is 
available, manuscript evaluation may be stalled until the 
issue is resolved. 
A certain degree of image processing is acceptable for 
publication (and for some experiments, fields and 
techniques is unavoidable), but the final image must 
correctly represent the original data and conform to 
community standards. The guidelines below will aid in 
accurate data presentation at the image processing level. 
• Authors should list all image acquisition tools and 
image processing software packages used. Authors 
should document key image-gathering settings and 
processing manipulations in the Materials and 
Methods section. 
• Images gathered at different times or from different 
locations should not be combined into a single 
image, unless it is stated that the resultant image is 
a product of time-averaged data or a time-lapse 
sequence. If juxtaposing images is essential, the 
borders should be clearly demarcated in the figure 
and described in the legend. 
• Touch-up tools, such as cloning and healing tools 
in Photoshop, or any feature that deliberately 
obscures manipulations are to be avoided. 
• Processing (such as changing brightness and 
contrast) is appropriate only when it is applied 
equally across the entire image and is applied 
equally to controls. Contrast should not be 
adjusted so that data disappear. Excessive 
manipulations, such as processing to emphasize 
one region in the image at the expense of others 
(for example, through the use of a biased choice of 
threshold settings), is inappropriate, as is 
emphasizing experimental data relative to the 
control. 
Positive and negative controls, as well as molecular size 
markers, should be included on each gel and blot - either in 
the main figure or an expanded data supplementary figure. 
The display of cropped gels and blots in the main paper is 
encouraged if it improves the clarity and conciseness of the 
presentation. In such cases, the cropping must be mentioned 
in the figure legend. 
• Vertically sliced gels that juxtapose lanes that were 
not contiguous in the experiment must have a clear 
separation or a black line delineating the boundary 
between the gels. 
• Cropped gels in the paper must retain important 
bands.  
• Cropped blots in the body of the paper should 
retain at least six band widths above and below the 
band.  
• High-contrast gels and blots are discouraged, as 
overexposure may mask additional bands. Authors 
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should strive for exposures with gray 
backgrounds. Immunoblots should be surrounded 
by a black line to indicate the borders of the blot, if 
the background is faint. 
• For quantitative comparisons, appropriate 
reagents, controls and imaging methods with 
linear signal ranges should be used. 
Microscopy adjustments should be applied to the entire 
image. Threshold manipulation, expansion or contraction of 
signal ranges and the altering of high signals should be 
avoided. If pseudo-coloring and nonlinear adjustment (for 
example, "gamma changes") are used, this must be 
disclosed. Adjustments of individual color channels are 
sometimes necessary on merged images, but this should be 
noted in the figure legend.  
Correction and retraction policy 
 
We recognize our responsibility to correct errors. Content 
published online is final and cannot be amended without 
formal notice.  
Please note the following policy for making corrections to 
Molecular Therapy — Methods & Clinical Development peer-
reviewed content: 
• Erratum. Notification of an important error made 
by the journal or publisher that affects the 
publication record or the scientific integrity of the 
paper or the reputation of the authors, or of the 
journal. 
• Corrigendum. Notification of an important error 
made by the author that affects the publication 
record or the scientific integrity of the paper or the 
reputation of the authors or the journal. 
• Retraction. Notification of invalid results. All 
coauthors must sign a retraction specifying the 
error and stating briefly how the conclusions are 
affected. 
Decisions about corrections are made by the Editor 
(sometimes with advice of peer reviewers) and this 
sometimes involves author consultation. Requests to make 
corrections that do not affect the paper in a significant way 
or impair the reader's understanding of the contribution (a 
spelling mistake or grammatical error, for example) are not 
considered. 
In cases where coauthors disagree about a correction, the 
Editor will take advice from independent peer reviewers 
and impose the appropriate correction, noting the 
dissenting author(s) in the text of the published version. 
Availability of data and materials 
An inherent principle of publication is that others should be 
able to replicate and build upon the authors' published 
claims. Therefore, a condition of publication is that authors 
are required to make materials, data, and associated 
protocols available in a publicly accessible database. Where 
one does not exist, the information must be made available 
to referees at submission and to readers promptly upon 
request. Any restrictions on material availability or other 
relevant information must be disclosed in the manuscript's 
Materials and Methods section and should include details of 
how materials and information may be obtained. 
The Editors reserve the right, when they believe it is 
justified, to require authors to submit original data for 
confidential reanalysis by a statistician on behalf of the 
journal. 
Submission of DNA sequences 
The editorial policy of Molecular Therapy — Methods & 
Clinical Development is to require the use of databases. 
Deposititon of data in the appropriate database(s) is a 
condition of publication. New nucleotide data must be 
submitted and deposited in the DDBJ/EMBL/GenBank 
databases and an accession number obtained before the 
paper can be accepted for publication. Submission to any 
one of the three collaborating databanks is sufficient to 
ensure data entry in all. The accession number should be 
included in the manuscript. If requested, the database will 
withhold release of data until publication. The most 
convenient method for submitting sequence data is via the 
Internet: 
DDBJ via SAKURA 
EMBL via WEBIN 
GenBank via BankIt 
stand-alone submission tool Sequin  
Mouse Genome Informatics 
For special types of submissions (for example, genomes, 
bulk submissions, and so on) additional submission 
protocols are available from the above sites. 
Database contact information: 
DDBJ: Center for Information Biology and DNA Data Bank 
of Japan, National Institute of Genetics: ddbj@ddbj.nig.ac.jp; 
http://www.ddbj.nig.ac.jp/; Visit DDBJ's website 
EMBL: EMBL Nucleotide Sequence Submissions, European 
Bioinformatics Institute: datasubs@ebi.ac.uk;  Visit EMBL's 
website 
GenBank: National Center for Biotechnology Information, 
National Library of Medicine: info@ncbi.nlm.nih.gov; Visit 
GenBank's website 
Bioethics 
Human and other animal experiments 
For primary research manuscripts reporting experiments on 
live vertebrates and/or higher invertebrates, the 
corresponding author must confirm that all experiments 
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were performed in accordance with relevant guidelines and 
regulations. The manuscript must include a statement 
identifying the institutional and/or licensing committee 
approving the experiments, including any relevant details 
regarding animal welfare, patient anonymity, drug side 
effects, and informed consent. 
For experiments involving human subjects, authors must 
identify the committee approving the experiments and 
include with their submission a statement confirming that 
informed consent was obtained from all subjects. See 
Clinical Trials section for more information. 
Biosecurity policy 
The Editor may also seek advice about submitted papers 
that raise concerns. These may include, for example, ethical 
issues or issues of data or materials access. Very 
occasionally, concerns may also relate to the implications of 
publishing a paper to the society, including threats to 
security. In such circumstances, advice will usually be 
sought simultaneously with the technical peer-review 
process. As in all publishing decisions, the decision whether 
to publish is at the discretion of the Editor. 
 
Communication 
Communication with the media 
Material submitted must not be discussed with the media. 
We reserve the right to halt the consideration or publication 
of a paper if this condition is broken. If a paper is 
particularly newsworthy, NPG may send a press release to 
our list of journalists in advance of publication with an 
embargo that forbids any coverage of the manuscript, or the 
findings of the manuscript, until the time and date clearly 
stated, which will coincide with when the paper is 
publishing online. Authors whose papers are scheduled for 
publication may also arrange their own publicity (for 
instance, through their institution's press offices), but they 
must strictly adhere to the online publication press embargo 
and are advised to coordinate their own publicity with 
NPG's press office. 
Communication between scientists 
Molecular Therapy — Methods & Clinical Development does not 
wish to hinder communication between scientists. You are 
free to communicate with other researchers as much as you 
wish, whether on a recognized community preprint server 
by discussion at scientific meetings or by online 
collaborative sites such as wikis, but we do not encourage 
premature publication by discussion with the press (beyond 
a formal presentation, if at a conference).
 
FURTHER INFORMATION 
 
 
For inquiries related to submission requirements, please contact the editorial office. For inquiries related to advertising, 
permissions, papers in production or publishing a supplement, please contact the publisher’s office.  
